Lombard Odier Asset Management (Switzerland) Sa Fate Therapeutics Inc Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $183,763 - $314,948	-8,734 Reduced 6.76%	120,479 $2.7 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $748,751 - $1.79 Million	-42,112 Reduced 24.58%	129,213 $3.2 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $2.99 Million - $6.07 Million	-100,686 Reduced 37.02%	171,325 $6.64 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $6.94 Million - $9.34 Million	145,101 Added 114.33%	272,011 $15.9 Million
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $7.52 Million - $12.1 Million	126,910 New	126,910 $7.52 Million

Others Institutions Holding FATE

# of Institutions

177

Shares Held

113M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $133M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account